FY2028 EPS Estimates for Personalis Reduced by HC Wainwright

Personalis, Inc. (NASDAQ:PSNL - Free Report) - Analysts at HC Wainwright reduced their FY2028 EPS estimates for shares of Personalis in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.40 per share for the year, down from their prior forecast of $0.53. HC Wainwright has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Personalis' current full-year earnings is ($1.15) per share.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.10. The firm had revenue of $22.58 million during the quarter, compared to analysts' expectations of $19.81 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 72.35%. During the same quarter last year, the company posted ($0.50) EPS.

PSNL has been the subject of several other research reports. Needham & Company LLC reiterated a "buy" rating and set a $7.25 price target on shares of Personalis in a research report on Thursday. BTIG Research lifted their price target on Personalis from $5.50 to $7.00 and gave the company a "buy" rating in a research note on Friday, August 16th.

Personalis Stock Performance

PSNL stock traded up $0.07 during trading on Friday, hitting $4.39. The company had a trading volume of 887,156 shares, compared to its average volume of 715,371. The firm has a 50-day moving average price of $5.15 and a 200-day moving average price of $3.32. Personalis has a 12 month low of $0.89 and a 12 month high of $7.20.

Institutional Investors Weigh In On Personalis

A number of hedge funds and other institutional investors have recently modified their holdings of PSNL. ARK Investment Management LLC increased its holdings in shares of Personalis by 11.4% during the third quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company's stock worth $38,120,000 after purchasing an additional 723,637 shares during the period. Semanteon Capital Management LP bought a new position in Personalis during the 3rd quarter worth $375,000. International Assets Investment Management LLC raised its holdings in Personalis by 438.0% in the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company's stock valued at $113,000 after acquiring an additional 17,082 shares in the last quarter. nVerses Capital LLC bought a new stake in shares of Personalis during the 3rd quarter valued at $40,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in shares of Personalis by 42.5% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company's stock worth $81,000 after purchasing an additional 4,504 shares in the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.